An Exploratory Tumor Biopsy-Driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Immunomodulatory Treatment-Naïve Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Receiving REGN2810 (Anti-PD-1)
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2018
At a glance
- Drugs Cemiplimab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 07 Jun 2018 Planned End Date changed from 6 Aug 2019 to 20 Apr 2020.
- 07 Jun 2018 Planned primary completion date changed from 12 Sep 2018 to 17 May 2019.
- 15 Nov 2017 Planned End Date changed from 23 Aug 2019 to 6 Aug 2019.